相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gilbert syndrome redefined: A complex genetic haplotype influences the regulation of glucuronidation
Ursula Ehmer et al.
HEPATOLOGY (2012)
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study
M. Filopanti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Combined effect of ADH1B rs1229984, rs2066702 and ADH1C rs1693482/rs698 alleles on alcoholism and chronic liver diseases
Reka Toth et al.
DISEASE MARKERS (2011)
Medical therapy in acromegaly
Mark Sherlock et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Genetics of alcohol dependence
Mitsuru Kimura et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2011)
Variability in Ethanol Biodisposition in Whites Is Modulated by Polymorphisms in the ADH1B and ADH1C Genes
Carmen Martinez et al.
HEPATOLOGY (2010)
Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert's Syndrome
Ignacio Bernabeu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
S. J. C. M. M. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas
M. Filopanti et al.
PHARMACOGENOMICS JOURNAL (2008)
Alcoholism and alcohol drinking habits predicted from alcohol dehydrogenase genes
Janne Schurmann Tolstrup et al.
PHARMACOGENOMICS JOURNAL (2008)
Long-term efficacy and safety of combined treatment of somatostatin analogs and Pegvisomant in acromegaly
Sebastian J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies
Rob Webster et al.
DRUG METABOLISM AND DISPOSITION (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on lGF-I levels, tumor mass, hypertension and glucose tolerance
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis
H Biering et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Allelic variation at alcohol metabolism genes (ADH1B, ADH1C, ALDH2) and alcohol dependence in an American Indian population
CJ Mulligan et al.
HUMAN GENETICS (2003)
Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians
C Köhle et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome
WHM Peters et al.
JOURNAL OF HEPATOLOGY (2003)
Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
JJ Kopchick et al.
ENDOCRINE REVIEWS (2002)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
